Informations générales
  • Catégorie de maladie Recherche de base (anatomie/physiologie) (BASEC)
  • État du recrutement recrutement terminé (BASEC/ICTRP)
  • Lieu de l’étude
    Luzern, Zurich
    (BASEC)
  • Responsable de l'étude Dr. sc. Dr. med. Milan Scheidegger, MA HPK milan.scheidegger@bli.uzh.ch (BASEC)
  • Source(s) de données BASEC: Importé de 10.02.2026 ICTRP: N/A
  • Date de mise à jour 10.02.2026 15:44
HumRes55291 | SNCTP000004416 | BASEC2021-00180

Neuroimaging Study (MRI) on Mindfulness Meditation under Pharmacological Stimulation with DMT and Harmin

  • Catégorie de maladie Recherche de base (anatomie/physiologie) (BASEC)
  • État du recrutement recrutement terminé (BASEC/ICTRP)
  • Lieu de l’étude
    Luzern, Zurich
    (BASEC)
  • Responsable de l'étude Dr. sc. Dr. med. Milan Scheidegger, MA HPK milan.scheidegger@bli.uzh.ch (BASEC)
  • Source(s) de données BASEC: Importé de 10.02.2026 ICTRP: N/A
  • Date de mise à jour 10.02.2026 15:44

Résumé de l'étude

We are conducting this project to investigate potential neurophysiological synergy effects between mindfulness meditation and psychedelics. Previous studies have found that both mindfulness and psychedelics such as psilocybin modulate the neural activity and connectivity of the same brain network. However, little is known about the potential interactions between mindfulness meditation and psychedelics. Particularly interesting for the combination with mindfulness meditation is the indigenous plant preparation "Ayahuasca". It contains two components, N,N-Dimethyltryptamine (DMT) and Harmin, which are very similar to the body's neurotransmitter serotonin and enhance its effect in the body. We now want to find out how these corresponding networks change in experienced meditators after DMT/Harmin-enhanced mindfulness meditation and how this affects their subjective experience. For this purpose, we apply functional MRI imaging, as well as psychometric questionnaires and detailed experiential interviews before and after a three-day meditation retreat. Participants will be randomly assigned to one of two groups. One group will receive DMT and Harmin during the seated meditation on the second day, while the other group will receive a corresponding placebo. Neither the participants nor the investigator know who receives a placebo or the combination of DMT/Harmin on the day of the trial. The pre- and post-measurements of the MRI imaging and psychometric questionnaires of the DMT/Harmin group will be compared with those of the placebo control group. By investigating the synergistic effects of mindfulness meditation and DMT/Harmin, the aim of this study is to contribute to a comprehensive understanding of the neurophenomenology of rare and hard-to-access consciousness phenomena.

(BASEC)

Intervention étudiée

Our goal is to induce a changed state of consciousness (compared to placebo) through sequential incremental administration of DMT in combination with Harmin in experienced meditators within the framework of a meditation retreat and to investigate this with neurophenomenological methods (double-blind, randomized, placebo-controlled study).

(BASEC)

Maladie en cours d'investigation

Healthy subjects

(BASEC)

Critères de participation
- Physically and psychologically healthy - Age of 25-60 years - Meditation experience of at least 1000 hours of formal meditation, preferably in Mahayana (Zen), Theravada (Vipassana) or Mahamudra/Dzogchen, as well as prior retreat experience (BASEC)

Critères d'exclusion
- Use of medications and drugs - MRI exclusion criterion: metal parts in the body - For women: pregnancy or breastfeeding (BASEC)

Lieu de l’étude

Luzern, Zurich

(BASEC)

non disponible

Sponsor

Dr. sc. Dr. med. Milan Scheidegger, Psychiatrische Universitätsklinik Zürich und Universität Zürich

(BASEC)

Contact pour plus d'informations sur l'étude

Personne de contact en Suisse

Dr. sc. Dr. med. Milan Scheidegger, MA HPK

+41 (0)79 436 13 92

milan.scheidegger@bli.uzh.ch

Psychiatrische Universitätsklinik Zürich und Universität Zürich

(BASEC)

Informations scientifiques

non disponible

Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)

Commission cantonale de Zurich

(BASEC)

Date d'approbation du comité d'éthique

18.05.2021

(BASEC)


Identifiant de l'essai ICTRP
non disponible

Titre officiel (approuvé par le comité d'éthique)
Mindfulness and Psychedelics: A combined neurophenomenological and pharmacological approach to the characterization of mindfulness states in experienced meditators (BASEC)

Titre académique
non disponible

Titre public
non disponible

Maladie en cours d'investigation
non disponible

Intervention étudiée
non disponible

Type d'essai
non disponible

Plan de l'étude
non disponible

Critères d'inclusion/exclusion
non disponible

non disponible

Critères d'évaluation principaux et secondaires
non disponible

non disponible

Date d'enregistrement
non disponible

Inclusion du premier participant
non disponible

Sponsors secondaires
non disponible

Contacts supplémentaires
non disponible

ID secondaires
non disponible

Résultats-Données individuelles des participants
non disponible

Informations complémentaires sur l'essai
non disponible

Résultats de l'essai

Résumé des résultats

20251103-dhm-laysummary.pdf

Lien vers les résultats dans le registre primaire

non disponible